Sino Medical has issued an announcement, expecting net profit attributable to shareholders of the listed company for the first half of 2026 to be 50.33 million yuan, a year-on-year increase of 263.66%. The profit growth is mainly due to the continued volume expansion of coronary business products and significant sales growth of new neuro business products, with operating revenue rising 26.68% year-on-year. At the same time, cost control has been effective and research and development expenses have declined.
Sino Medical Sciences Technology InExpects net profit to rise 263.66% due to volume expansion of coronary products and significant sales growth of new neuro products.